You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Dow
Johnson and Johnson
Moodys
Mallinckrodt

Last Updated: October 21, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PAZOPANIB HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Pazopanib Hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT02810756 Study With Improved Solubility Pazopanib Not yet recruiting The Netherlands Cancer Institute Phase 0 2016-09-01 The pharmacokinetics of a new formulation with Pazopanib will be studied. This will be done in a patient cohort of n = 12.
New Combination NCT03571438 Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors Recruiting University Hospital, Grenoble N/A 2017-10-16 The investigators objective is to test the combination directly on organotypic cultures of tumors from patients after their excision in the Department of Urology and Renal Transplantation of the University Hospital of Grenoble and to compare their efficacy with that of currently selected treatments in the clinic. The population targeted by the combination for use in clinical practice is patients with metastatic clear cell renal cell carcinoma. Current treatments for these patients are Sunitinib, Pazopanib and Temsirolimus.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Pazopanib Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00244764 GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Completed GlaxoSmithKline Phase 2 2005-10-01 Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
NCT00256880 Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma Completed GlaxoSmithKline Phase 2 2005-01-01 The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.
NCT00297258 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma Completed GlaxoSmithKline Phase 2 2005-11-01 The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.
NCT00334282 Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Completed GlaxoSmithKline Phase 3 2006-04-01 To evaluate efficacy and safety of pazopanib compared to placebo in patients with locally advanced and/ or metastatic renal cell carcinoma (RCC). Approximately 350-400 eligible patients will be stratified and randomized in a 2:1 ratio to receive either 800 mg pazopanib once daily or matching placebo. The study treatment will continue until patients experience disease progression, unacceptable toxicity or death. Primary objective of the study is to evaluate and compare the two treatment arms for progression-free survival. Principal secondary objective is to evaluate and compare the two treatment arms with respect to overall survival. Other objectives are overall response rate [complete response (CR) + partial response (PR)], rate of CR + PR + 6 months stable disease, and the incidence, severity and causality of adverse events and serious adverse events. Safety and efficacy assessments will be regularly performed on all patients. An Independent Data Monitoring Committee will be established to monitor safety during the course of the study and to evaluate interim efficacy data on overall survival.
NCT00347919 Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer Completed GlaxoSmithKline Phase 2 2006-07-01 This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the ErbB2 protein.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pazopanib Hydrochloride

Condition Name

Condition Name for Pazopanib Hydrochloride
Intervention Trials
Carcinoma, Renal Cell 27
Renal Cell Carcinoma 12
Sarcoma 11
Metastatic Renal Cell Carcinoma 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Pazopanib Hydrochloride
Intervention Trials
Carcinoma, Renal Cell 77
Carcinoma 70
Sarcoma 42
Lung Neoplasms 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Pazopanib Hydrochloride

Trials by Country

Trials by Country for Pazopanib Hydrochloride
Location Trials
United States 897
Germany 105
Italy 74
Canada 66
United Kingdom 43
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Pazopanib Hydrochloride
Location Trials
Texas 54
California 52
New York 38
Pennsylvania 36
Ohio 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Pazopanib Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Pazopanib Hydrochloride
Clinical Trial Phase Trials
Phase 4 8
Phase 3 15
Phase 2/Phase 3 4
[disabled in preview] 166
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Pazopanib Hydrochloride
Clinical Trial Phase Trials
Completed 92
Recruiting 59
Active, not recruiting 48
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Pazopanib Hydrochloride

Sponsor Name

Sponsor Name for Pazopanib Hydrochloride
Sponsor Trials
GlaxoSmithKline 101
National Cancer Institute (NCI) 43
Novartis 18
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Pazopanib Hydrochloride
Sponsor Trials
Other 226
Industry 164
NIH 43
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Dow
Medtronic
Mallinckrodt
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.